Epidemiological studies have suggested that prostatitis may increase the risk of prostate cancer due to chronic inflammation. We studied the association between several genitourinary infections and the risk of prostate cancer based on data from the EPICAP study. EPICAP is a population-based case-control study conducted in the d epartement of H erault, France, between 2012 and 2014. A total of 819 incident cases and 879 controls have been face to face interviewed using a standardized questionnaire gathering information on known or suspected risk factors of prostate cancer, and personal history of genitourinary infections: prostatitis, urethritis, orchi-epididymitis, and acute pyelonephritis. Odds Ratios (OR) and their 95% confidence interval were estimated using multivariate unconditional logistic regression. Overall, 139 (18%) cases and 98 (12%) controls reported having at least one personal history of genitourinary infections (OR 5 1.64 [1.23-2.20]). The risk increased with the number of infections (p-trend < 0.05). The association was specifically observed with personal history of chronic prostatitis and acute pyelonephritis (5) (6) .92] and OR 5 2.66 [1. .51], respectively) and in men who did not use any non-steroidal anti-inflammatory drugs (OR 5 2.00 [1.37-2.91]). Our results reinforce the hypothesis that chronic inflammation, generated by a personal history of genitourinary infections, may play a role in prostate carcinogenesis.
Introduction
Prostate cancer is the first cancer in men in industrialized countries with an annual incidence in France of 98 per 100,000 men, which represents 53,917 new cases diagnosed in 2011. 1 Despite a relatively high morbidity and mortality (nearly 9,000 deaths in France in 2011), 2 only age, ethnicity and family history of prostate cancer are well established risk factors for this cancer. Apart from these factors, its etiology remains largely unexplained. Studies of migrants showed that the incidence rates of Chinese or Japanese populations living in the United States were much higher than those observed in their native countries suggesting the influence of environmental and lifestyle factors. 3 Chronic inflammation has been associated with the development of several cancers via a specific infectious or environmental agent. 4, 5 In this context, chronic prostatic inflammation may be involved in prostate carcinogenesis. 6, 7 Indeed, the presence of inflammatory infiltrates localized near zones of proliferative inflammatory atrophy and prostatic intraepithelial neoplasia, considered as pre-cancerous prostatic lesions, support the hypothesis of a possible link between chronic prostatic inflammation and prostate cancer. [6] [7] [8] Several epidemiological studies have suggested that infections with prostatic tropism may also play a role in prostatic carcinogenesis due to their own role or chronic inflammation. 9, 10 Among these infections, sexually transmitted infections and a personal history of prostatitis have received increasing attention in the past 20 years, and some have been positively associated with the risk of prostate cancer. [11] [12] [13] However, the results were contradictory from one study to another and few studies have investigated the relationship with the personal history of prostatitis, including the acute or chronic nature of prostatitis, the number of prostatitis, the delay between the history of prostatitis and the occurrence of prostate cancer or their role according to prostate cancer aggressiveness. Only a recent Canadian study has extended the study of a personal history of prostatitis to other genitourinary infections such as urethritis and orchi-epididymitis. 14 To date, no studies have investigated high urinary tract infections such as acute pyelonephritis.
In this context, our main objective was to study the role of several genitourinary infections in the occurrence of prostate cancer based on data from the EPICAP study.
Methods

Study selection
The Epidemiological study of Prostate Cancer (EPICAP) is a population-based case-control study carried out in the d epartement of H erault, a well delimited geographic area in the South of France. Details of the EPICAP objectives and study design have been previously described elsewhere. 15 Briefly, eligible cases were all newly diagnosed prostate cancer cases in 2012-2013 in men under the age of 75 years old and residing in the d epartement of H erault at the time of diagnosis. All cases have been histologically confirmed.
The eligible controls were men randomly selected in the general population of H erault, residing in the d epartement of H erault, who did not declare a prostate cancer when they were included in the study and frequency matched to the cases by 5-year age group. Quotas on socioeconomic status have been defined to yield the control group comparable to the population of H erault of the same age.
Overall, among the 1,098 eligible cases and the 1,109 eligible controls, 819 cases and 879 controls have been included in the study with a participation rate of 75% and 79%, respectively.
Data collection
In-person interviews of cases and controls were conducted by trained clinical research nurses using a standardized questionnaire that gathered detailed information on socioeconomic characteristics, personal medical history, family history of cancer, lifestyle, residential and occupational history.
Men were asked about whether they had had a personal history of prostatitis, urethritis, orchi-epididymitis or acute pyelonephritis. The number of each infection and the date at onset as well as the acute or chronic nature for prostatitis were also collected.
Case-specific medical data were collected by the clinical research nurses from the medical records at the time of diagnosis and completed by the H erault cancer registry (PSA value, Gleason Score, and stage at diagnosis).
Statistical analysis
Personal history of each infection (prostatitis, acute pyelonephritis, urethritis, orchi-epididymitis), based on self-report, was defined as at least one infection of interest occurring before the reference date (date of diagnosis for the cases and date of interview for the controls). Group 1 genitourinary infections was defined as at least a personal history of prostatitis, urethritis or orchi-epididymitis while Group 2 genitourinary infections was defined as at least a personal history of prostatitis, urethritis, orchi-epididymitis or acute pyelonephritis. No personal history of any infection was considered as the reference group.
All analyses were performed using SAS 9.4 (SAS Inc., Cary, North Carolina).
Odds ratios (OR) and their 95% confidence intervals (95% CI) were estimated using an unconditional logistic regression to investigate associations between genitourinary infections and the risk of prostate cancer. All analyzes were systematically adjusted for age, ethnicity and family history of prostate cancer. We also adjusted analyses for potential confounding factors such as educational level and body mass index.
All analyses were performed taking into account the aggressiveness of the tumor based on the Gleason score at diagnosis (low aggressiveness: Gleason score < 7, intermediate aggressiveness: Gleason score 5 7 including subjects for whom the two grades are 3 1 4, as well as those for which the two most commonly represented grades in the tumor are not known (n 5 13), high aggressiveness: Gleason score 7 including subjects for whom the sum of the two most frequently represented grades in the tumor analyzed is >7 and those for which the two grades are 4 1 3.
What's new?
Epidemiological studies have suggested that infections with prostatic tropism may increase the risk of prostate cancer due to chronic inflammation. But the results so far have been contradictory, and further detail is needed. Here, using data from the EPICAP study in France, the authors found an association between a personal history of genitourinary infections and prostate cancer occurrence, especially chronic prostatitis. Furthermore, associations were specifically observed in men who did not use any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The results reinforce the hypothesis that chronic inflammation, generated by a personal history of genitourinary infections, may play a role in prostate carcinogenesis.
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Analyses were also stratified according to the use of NonSteroidal Anti-Inflammatory Drugs (NSAIDs), based on the Ever/Never variable as described in a previous paper from EPICAP. 16 Finally, sensitivity analyses have been performed in order to test the robustness of our results. In particular, we restricted the control group to those who reported having a history of a normal screening for prostate cancer and to those who reported receiving PSA tests (2-5 tests, >5 tests, and 2 tests).
Results
The characteristics of the study population are presented in Table 1 . Age in 5-year groups, ethnic origin, educational level, smoking status and body mass index were similarly distributed between cases and controls (p 5 0.14, p 5 0.23, p 5 0.37, p 5 0.08, p 5 0.91, respectively). As expected in the literature, a family history of prostate cancer in first-degree relatives was more frequent in cases than in controls (p < 0.0001). Table 2 presents the associations between each genitourinary infection of interest and the risk of occurrence of prostate cancer as well as the associations for all genitourinary infections (Group 1, Group 2). We observed a prevalence of a personal history of prostatitis of 10% in cases and 7% in controls (OR: 1.49, 95% CI: 1.05-2.12). This association was specifically observed in men with a personal history of chronic prostatitis (OR: 2.95, 95% CI: 1.26-6.92), while no association was observed with the number of prostatitis.
A significant association was also observed with a personal history of acute pyelonephritis (OR: 2.66, 95% CI: 1.29-5.51). In contrast, no association was observed with a personal history of urethritis or orchi-epididymitis.
Overall, the prevalence of all genitourinary infections (Group 2) in our population was 18% in cases and 12% in controls (OR: 1.64, 95% CI: 1.23-2.20). The risk of prostate cancer increased with the number of infections either for Group 1 or Group 2 (OR: 2.26, 95% CI: 0.90-5.68 for two or more infections, OR: 2.45, 95% CI: 1.04-5.76 for 2 or more infections, respectively for Group 1 and Group 2 -p trend for both groups <0.05).
All associations were more specifically observed for low aggressive and high aggressive prostate cancer (Table 3) . A personal history of all genitourinary infections (Group 2) was positively associated with low aggressive (OR: 2.19, 95% CI: 4 Group 2 genitourinary infection: personal history of prostatitis, urethris, orchi-epididymitis or acute pyelonephritis. Cancer Epidemiology Table 5 shows the sensitivity analyses that have been performed by restricting the control group to those who reported PSA tests. All previous observed associations became not statistically significant, but our analyses were based on small numbers (number of controls 5 248 for 2-5 tests, number of controls 5 359 for >5 tests, and number of controls 5 607 for 2 tests).
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Discussion
The main finding of our study was the association between a personal history of genitourinary infections and prostate cancer occurrence, particularly due to a personal history of chronic prostatitis. All associations were observed in particular for low and high aggressive prostate cancers.
Our findings are based on a large, carefully designed population-based case-control study conducted specifically to assess environmental and genetic factors in prostate cancer risk. 15 The completion of our study within the general population, the establishment of quotas on age (controls comparable to cases) and on socioeconomic status (controls comparable to the general population of H erault), and the absence of a possible survival bias (eight deaths among eligible cases which represents 0.7% of the eligible cases) allow to minimize a potential selection bias and thus constituted one of the strengths of our study.
However, a limitation of our study was the self-reporting of genitourinary infections, which could lead to a possible bias either in memory or classification. Nevertheless, the data collection based on a standardized questionnaire, the similar interview conditions in cases and controls, the specificity of the observed associations (personal history of chronic prostatitis and acute pyelonephritis), a prevalence of a personal history of prostatitis comparable to that observed in other studies 17 and the dose-response relationship observed for all genitourinary infections allow to minimize a potential classification bias and to be confident in our results. Our results also raised the possibility of a possible detection bias. Nevertheless, the average time between the personal history of prostatitis and the reference date was 16.7 years for cases of 10.7 years controls (p 5 0.09; data not shown), which is not in favor of a possible detection bias. Analyzes performed in men who did not report a personal history of benign prostatic hyperplasia did not modify our results. The sensitivity analysis restricting the control group to those who reported having more different number of PSA tests, slightly decreased the observed estimations which became statistically not significant, which does not allow us to completely ruled out a detection bias.
Finally, our results remained unchanged when taking into account well established risk factors such as family history of prostate cancer and ethnic origin, and potential confounding factors such as educational level and body mass index.
To date, 33 studies have investigated the role of a personal history of prostatitis in prostate cancer risk. With the exception of two studies, a Canadian population-based case-control study 14 and an American nested case-control study, 18 all of these studies were included in two meta-analyzes including case-control studies carried out between 1971 and 2012.
12,13
The meta-ORs were 1.57, 95% CI: 18 and an association for a personal history of prostatitis lasting longer than 1 year. 19 Similarly, only the Canadian study investigated other lower genitourinary infections than prostatitis which observed an increased risk of prostate cancer for all genitourinary infections (OR:1, 34, 95% CI: 1.14-1.58). We observed very similar results with an OR of 1.46, 95% CI: 1.08-1.98 and 1.64, 95% CI: 1.23-2.20 when we also included the personal history of acute pyelonephritis, that has never studied in the literature. Pyelonephritis is a high urinary infection very rare in humans, which may nevertheless reflect the consequences of symptomatic prostatitis. Very few studies had information about whether or not prostate cancer was aggressive. The associations observed specifically in subjects with low Gleason score and high Gleason score were similar to those observed in the Canadian study. These results could be explained by a possible detection bias for associations observed in low Gleason score cases. On the other hand, the associations observed in men with high Gleason scores were in favor of a more aggressive cancer risk in men with a history of genitourinary infection.
To our knowledge, the EPICAP study is the first study to examine the role of prostatitis and other genitourinary infections according to the use of non-steroidal anti-inflammatory drugs. Associations were specifically observed in men who did not use any Non-Steroidal Anti-Inflammatory Drugs which strongly suggests that infections with prostatic tropism may play a role in prostatic carcinogenesis through a chronic inflammation mechanism. Since April 2016, the US Preventive Services Task Force recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease and colorectal cancer. 20 In the same way, the potential implications of our results, if confirmed, may be a targeted primary prevention with NSAIDs, remains to define which one, in men with a personal history of prostatitis, or other genitourinary infections.
In conclusion, our results reinforce the hypothesis that chronic inflammation, generated by a history of genitourinary infections, may play a role in prostatic carcinogenesis.
